OxcarbazepineThird Party Manufacturing in India

Oxcarbazepine is a prodrug that is rapidly converted to its pharmacologically active 10-monohydroxy metabolite (MHD, licarbazepine). The precise mechanism by which oxcarbazepine and MHD exert their anticonvulsant effect involves blockade of voltage-sensitive sodium channels. By binding to the inactivated state of these channels, MHD stabilizes hyperexcited neural membranes, inhibits repetitive neuronal firing, and reduces the propagation of synaptic impulses. Unlike carbamazepine, oxcarbazepine is not metabolized through the cytochrome P450 system to an epoxide intermediate, resulting in fewer drug interactions and improved tolerability. The drug also modulates high-voltage activated calcium channels and increases potassium conductance, which further contribute to its antiseizure activity. These combined actions make oxcarbazepine effective for controlling partial-onset seizures with minimal hepatic enzyme induction compared to older anticonvulsants.

Therapeutic Uses

Oxcarbazepine is prescribed for the treatment of:

• Partial-onset seizures (Monotherapy): Approved for adults and children aged 4 years and above as a standalone treatment for focal epilepsy.
• Partial-onset seizures (Adjunctive therapy): Used in combination with other antiepileptic drugs for adults and children aged 2 years and above with partial seizures.
• Trigeminal neuralgia (off-label): Frequently prescribed off-label for neuropathic pain conditions, particularly trigeminal neuralgia, where sodium channel blockade provides pain relief.

Why Manufacturers Choose Oxcarbazepine

Oxcarbazepine is one of the most widely prescribed anticonvulsants globally, with consistent demand across both developed and emerging markets. Its superior safety profile compared to carbamazepine, particularly the absence of an epoxide metabolite and reduced risk of agranulocytosis, makes it a preferred choice for prescribers. The molecule is commercially available in multiple dosage forms including immediate-release tablets, sustained-release formulations, and oral suspensions, providing manufacturing flexibility. Indian manufacturers hold a significant share of the global oxcarbazepine API and formulation market, driven by WHO-GMP certified facilities capable of exporting to regulated markets including the US, UK, and EU. The growing epilepsy prevalence and increasing diagnosis rates in developing countries ensure sustained demand for oxcarbazepine third party manufacturing in India.